All our News | Provepharm

All our News

Our CSR report, published for seven years on the Global Compact website, has become an essential medium for promoting our voluntary and ambitious approach to all of our stakeholders.

BLUDIGO™ first indigotindisulfonate sodium, USP, injection drug product approved by FDA.


Act to improve life.


Act is the commitment tomobilize our resources to achieve our mission.

Act is daring to refuse the status quo and to define new standards of innovation.

Provepharm will participate in the HOPIPHARM Francophone Congress of Hospital Pharmacy, which will take place from 18 to 20 May 2022 at the Lille Congress Center.


Our CSR approach expands a little more each year and remains a central element of our strategy. To manage it effectively, it was necessary to equip ourselves with a tool to measure, improve and communicate our CSR actions.

Provepharm will be closer to healthcare professionals at the JFHOD congress from March 17 to 20, 2022 at the Palais des Congrès in Paris, and at the EAHP congress from March 23 to 25, 2022 in Vienna, Austria.


The form changes but not the substance...